Amiodarone Attenuates the Proarrhythmic Effects of Dobutamine in Patients with Advanced Congestive Heart Failure

ELEFtherIA P. TSAGALOU1, PANTElIS GOuNOPOULOS1, JOHN V. TERRoVITIS1, STAVROS G. DRACOS1, FOtIOS T. KATSAros1, ELISABETH E. KAldaRA1, GEORGE P. ALEXOPOULOS2, MAria I. ANASTASIou-NA NA2

13rd Cardiology Department and 2Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Introduction: The long-term use of positive inotropic pharmaceuticals in patients suffering from end-stage congestive heart failure (CHF) has been associated with increased mortality, presumed to be due to proarrhythmia. Oral amiodarone combined with intermittent dobutamine infusions (IDI), on the other hand, has been shown to increase survival. This study evaluated the effects of oral amiodarone on the arrhythmias caused by dobutamine in patients with advanced CHF.

Methods: Thirty patients with CHF, in New York Heart Association functional class III or IV despite optimal medical therapy, were treated with weekly 8-h infusions of dobutamine 10 µg/kg/min. All patients were treated for ≥1 month with oral amiodarone, 400 mg/day, before initiation of IDI. A 24-h ambulatory electrocardiogram was recorded on the day before dobutamine infusion and repeated the next day, starting with the onset of infusion.

Results: The average heart rate on the 24-h ambulatory electrocardiogram was 72 ± 14 beats/min before vs. 72 ± 12 beats/min during IDI (p=1.000). Likewise, dobutamine did not increase the frequency of premature ventricular complexes (23 ± 32 per h before vs. 42 ± 69 per h during infusion, p=0.131), ventricular couplets (18 ± 36 per 24 h vs. 17 ± 28 per 24 h, p=0.859), or the incidence of non-sustained ventricular tachycardia (27% vs. 40%, p=0.383). No patient developed ventricular fibrillation or sustained ventricular tachycardia during or after IDI.

Conclusions: Chronic low-dose oral amiodarone attenuates the proarrhythmic effects of dobutamine, increasing the safety of ambulatory IDI.

Manuscript received: October 5, 2008; Accepted: March 4, 2009.

Address: Maria I. Anastasiou-Nana
24 Makedonias St.
104 33 Athens, Greece
e-mail: jnanas@ath.forthnet.gr

Key words: Amiodarone, inotropic therapy, dobutamine, proarrhythmia, heart failure.
cardia in experimental animals, and increases the incidence of ventricular arrhythmias (VT) in patients. We hypothesized that if amiodarone, a potent antiarrhythmic agent with anti-adrenergic properties and minimal negative inotropic effects, was added to dobutamine, it would attenuate the latter’s proarrhythmic effects. A significant survival benefit conferred by intermittent dobutamine infusions (IDI) combined with oral amiodarone was observed in two previous controlled studies.

The aim of this study was to evaluate the effects of long-term oral amiodarone therapy on the arrhythmias induced by intravenous dobutamine in patients with advanced CHF.

Methods

Study population

The study population consisted of 30 consecutive patients with CHF refractory to optimal drug therapy, including digoxin, enalapril, spironolactone, and diuretics, who were successfully weaned from an initial 72-h infusion of dobutamine. All patients were either intolerant of treatment with metoprolol, 6.25 mg twice daily, or carvedilol, 3.125 mg twice daily, or beta-adrenergic blockade had been permanently discontinued at the time of the most recent episode of cardiac decompensation. The patients, who had not previously been treated with amiodarone, were placed on an oral regimen of 400 mg/day; recipients of implantable cardioverter-defibrillators received 800 mg/day. When hemodynamically stabilized, all patients underwent baseline clinical and laboratory evaluations, including echocardiography, radionuclide ventriculography, right heart catheterization and biochemical tests. They were then readmitted to the hospital for weekly 8-h IDI at a rate of 10 μg/kg/min. The first infusion began 2 to 4 weeks after the initial stabilization and continued for at least 6 months, regardless of the degree of clinical improvement, before weaning from inotropic therapy was attempted. In case of CHF exacerbation at any time during follow-up, episodes of paroxysmal nocturnal dyspnea in particular, the interval between IDI was shortened to <4 days, as necessary, until cardiac transplantation, if the patient was a candidate, or until death occurred.

Ambulatory monitoring

A 24-h ambulatory electrocardiogram (ECG) was recorded on the day before the first infusion of dobutamine, and on the next day, starting at the onset of dobutamine infusion and continuing for 15 h past the completion of infusion.

All 24-h ambulatory ECG recordings were processed by a core laboratory unaware of the treatment. Leads V1, V6, and aVF were analyzed on a Zymed model 2010 scanner (Zymed Medical Instruments, Camarillo, CA, USA). Computer-assisted rate measurements and arrhythmia analyses were performed with verification and editing by a technician. Noise and artifacts were deleted, and cardiac arrhythmias were quantified. A physician reviewed all final analyses.

Non-sustained (NS) VT was defined as ≥3 consecutive premature ventricular complexes (PVC) terminating spontaneously within 30 s. VT was defined as sustained if lasting >30 s, or requiring earlier termination because of hemodynamic collapse. Ventricular fibrillation (VF) was defined as a disorganized rhythm without a distinct QRS complex. We measured the changes from baseline in 1) maximum, minimum and average heart rates; 2) mean number of PVC per hour; and 3) numbers of ventricular couplets and episodes of VT/VF per 24 h.

The Cardiac Arrhythmia Pilot Study (CAPS) criteria were applied to determine whether individual increases in the density of ventricular arrhythmias between baseline and treatment with dobutamine were proarrhythmic. They included a ≥10-fold increase in PVC when baseline ectopy was 10 to 50 PVC/h, a ≥5-fold increase in PVC when ectopy at baseline was 51 to 100 PVC/h, a 4-fold increase in PVC when ectopy at baseline was 100 to 300 PVC/h, and a 3-fold increase in PVC when ectopy at baseline was ≥300 PVC/h. A ≥10-fold increase in runs of NSVT was also defined as proarrhythmic, regardless of the baseline frequency of episodes.

The Ethics Review Board of our institution approved this study, and all patients gave their informed consent to participate.

Statistical analyses

Categorical variables are presented as counts and percentages and continuous variables as mean ± standard deviation (SD). Student’s paired t-test was used to examine changes among individual patients. P-values <0.05 were considered statistically significant.

Results

The study included 30 patients with advanced CHF despite optimal medical therapy. Their baseline demo-


**Amiodarone Attenuates Proarrhythmic Effects of Dobutamine**

**Hellenic Journal of Cardiology**

Table 1. Baseline demographic, clinical and hemodynamic characteristics of the 30 patients included in the study.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>57 ± 13</td>
</tr>
<tr>
<td>Men/women, n</td>
<td>27/3</td>
</tr>
<tr>
<td>Ischemic/non-ischemic heart disease, n</td>
<td>15/15</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>100 ± 15</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>75 ± 20</td>
</tr>
<tr>
<td>Left ventricular end-diastolic diameter, mm</td>
<td>71 ± 6.9</td>
</tr>
<tr>
<td>Left ventricular end-systolic diameter, mm</td>
<td>58 ± 8.4</td>
</tr>
<tr>
<td>Left ventricular ejection fraction, %</td>
<td>22 ± 6</td>
</tr>
<tr>
<td>Mean right atrial pressure, mmHg</td>
<td>13 ± 6</td>
</tr>
<tr>
<td>Right ventricular systolic pressure, mmHg</td>
<td>58 ± 15</td>
</tr>
<tr>
<td>Mean pulmonary arterial pressure, mmHg</td>
<td>45 ± 10</td>
</tr>
<tr>
<td>Pulmonary capillary wedge pressure, mmHg</td>
<td>31 ± 6.4</td>
</tr>
<tr>
<td>Cardiac index, L/m²/min</td>
<td>2.2 ± 0.6</td>
</tr>
<tr>
<td>Pulmonary vascular resistance, Wood units</td>
<td>3.7 ± 2.6</td>
</tr>
<tr>
<td>New York Heart Association functional class</td>
<td>3.8 ± 0.4</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>1.8 ± 1.1</td>
</tr>
<tr>
<td>Serum sodium</td>
<td>137 ± 6.9</td>
</tr>
<tr>
<td>Drug therapy, n (% of patients):</td>
<td></td>
</tr>
<tr>
<td>Enalapril</td>
<td>20 (66)</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>11 (36)</td>
</tr>
<tr>
<td>Digoxin</td>
<td>12 (40)</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>30 (100)</td>
</tr>
<tr>
<td>Furosemide, mg/day</td>
<td>340 ± 180</td>
</tr>
</tbody>
</table>

Unless otherwise indicated, values are expressed as mean ± SD.

graphic, clinical and hemodynamic characteristics are given in Table 1.

**Ambulatory electrocardiogram analysis**

Dobutamine had no apparent proarrhythmic effects, neither during infusion nor during the 16 h following its completion (Table 2). There was no significant difference in average, minimum and maximum heart rates between baseline and the infusion period. PVC were recorded at baseline in all patients, ranging in number between 1 /24 h and 136 /h. On the day of dobutamine infusion, 28 of the 30 patients (93%) had PVC, ranging in number between 8 /24 h and 607 /h. There was no significant difference in the average rate of PVC between the two recordings. Ventricular couplets were recorded in 21 of 30 patients at baseline (70%), ranging in number between 1 and 172 /24 h. On the day of dobutamine infusion, 18 of the 30 patients (60%) had ventricular couplets ranging in numbers between 1 /24 h and 95 /24 h. There was no significant difference in the average rate of ventricular couplets between the two recordings. No patient developed sustained VT or VF.

Of the 8 patients (27%) with episodes of NSVT observed on the baseline 24-h ambulatory ECG recording, 4 had NSVT on the 24-h ambulatory ECG that included the dobutamine infusion. Eight patients (27%) with no episodes of NSVT at baseline developed between 1 and 18 episodes of NSVT on the day of dobutamine infusion. There was no significant difference in the average rate of NSVT between the two recordings. Using the CAPS criteria to define the clinically most significant ventricular arrhythmias, dobutamine was proarrhythmic in 4 patients (13%).

**Patients with ischemic versus non-ischemic heart disease**

When the 24-h ambulatory ECG recordings were analyzed according to the underlying heart disease, the dobutamine infusion did not change the heart rate or the frequency of ventricular arrhythmias either in patients with ischemic or in those with non-ischemic heart disease (Table 3). All patients who developed proarrhythmic effects according to the CAPS criteria suffered from idiopathic dilated cardiomyopathy.

**Infusion versus post-infusion period**

In a subgroup of 14 patients, the 24-h ambulatory ECG recordings were analyzed separately for the first 8 h, corresponding to the period of dobutamine infusion, and the next 16 h, corresponding to the post-infusion period. The average heart rate and the frequency of ventricular arrhythmias did not change from baseline either during dobutamine infusion or during the post-infusion period (Table 4).

**Discussion**

The present study used 24-h ambulatory ECG recordings to examine the effects of dobutamine on the heart rate and ventricular arrhythmias in patients with advanced CHF treated with long-term oral amiodarone. Dobutamine did not increase the heart rate or the frequency of ventricular arrhythmias, either during its infusion or in the post-infusion period.

Dobutamine is an inotropic pharmaceutical that improves the hemodynamic and clinical status of patients suffering from CHF refractory to standard treatment, though at the cost of an adverse effect on survival. Proarrhythmia is considered to be an impor-
tant contributor to this detrimental effect. Animal studies\textsuperscript{12} and clinical trials\textsuperscript{13-20} have suggested that dobutamine has a considerable proarrhythmic potential. The intravenous infusion of dobutamine in dogs with anterior myocardial infarction caused an increase in the inducibility of ventricular arrhythmias by programmed ventricular stimulation.\textsuperscript{12} Furthermore, the ventricular refractory period was longer in dogs with inducible than in those without inducible arrhythmias.\textsuperscript{12} In another animal study dobutamine caused either lengthening or shortening of the action potential duration in the non-ischemic myocardial zones, and a homogeneous and significant shortening of the action potential duration in ischemic zones, resulting in significant dispersion of repolarization.\textsuperscript{13}

These pre-clinical observations were confirmed in several studies of patients with CHF who received dobutamine, either in a chronic, intermittent manner,
or acutely for CHF decompensation. Vecchia et al reported a patient with chronic, severe CHF secondary to dilated cardiomyopathy, who developed QT prolongation and torsades de pointes VT during one cycle of intermittent low-dose dobutamine. David et al described 2 patients with refractory CHF, in whom low-dose dobutamine increased the density of complex ventricular arrhythmias significantly, including multifocal PVC and VT. Antiarrhythmic therapy suppressed the ventricular ectopy to baseline levels. An increased frequency of ventricular arrhythmias on 24-h ambulatory ECG by dobutamine, in patients with end stage CHF treated with IDI, was also reported by Tarján et al. The proarrhythmic effects of dobutamine subsided on the day after the infusion. Finally, Burger et al reported that dobutamine uniformly increased all forms of ventricular ectopy, compared to nesiritide, in patients with ischemic and non-ischemic heart disease and acutely decompensated CHF.

We found, in a previous non-randomized study, that the addition of oral amiodarone to IDI increased the survival of patients with refractory CHF, compared with patients who did not receive amiodarone. This observation was confirmed in a randomized double-blind placebo-controlled trial of 30 patients, where patients treated with dobutamine and amiodarone had a 60% reduction in the risk of death compared to the group treated with placebo and amiodarone.

In this study, all patients were treated with ≥400 mg/day of oral amiodarone for at least 1 month before the initiation of IDI. The 8-h dobutamine infusion did not cause significant changes in the 24-h ambulatory ECG measurements. The average heart rate remained unchanged during the infusion and the post-infusion period. This might be important, since heart rate is a major determinant of myocardial oxygen demand, and an increase in the latter in the context of advanced CHF, particularly in the presence of ischemic heart disease, can worsen the clinical status. The frequency of PVC, couplets and NSVT was also unchanged. The development of, or an increase in, ventricular ectopy and VT might also decrease stroke volume significantly, causing deceleration of CHF, and increase the likelihood of VF and death. Amiodarone attenuated the expected aggravation of ventricular arrhythmias by dobutamine, creating a safer environment for the administration of the inotrope.

The protective effects of amiodarone were expressed similarly in patients with ischemic and non-ischemic heart disease. This is particularly important, since inotropic therapy has been shown to be more harmful in patients with ischemic disease, antiarrhythmic protection might be particularly relevant for this subgroup of patients.

Despite our encouraging results, it is noteworthy that 4 patients met the CAPS criteria for proarrhythmia. While none of them developed sustained VT or VF, these patients might remain at risk of life-threatening arrhythmias during further dobutamine infusions. Meticulous avoidance of other factors that might also precipitate arrhythmias, such as electrolyte imbalance, probably in combination with higher amiodarone doses, might further increase the safety of dobutamine for these patients.

The precise mechanisms by which dobutamine increases the risk of arrhythmias are not clear, although prolongation of the ventricular refractory period and inhomogeneous repolarization have been suggested. Amiodarone, by homogeneously increasing repolarization, might attenuate the increase in dispersion of repolarization caused by dobutamine, decreasing the likelihood of reentrant tachycardia. Furthermore, the prevention of rate acceleration by the anti-adrenergic activity and intrinsic sympatholytic activity of amiodarone might prevent potential adverse effects on myocardial oxygen balance and consequent electrical instability, particularly in patients presenting with ischemic heart disease.

**Limitations of the study**

The most important limitation of the present study is its uncontrolled design. This, along with the spontaneous variability of ventricular ectopy in the setting of end stage CHF might have introduced biases. However, the patients served as their own controls, and several reports have already documented the proarrhythmic effects of dobutamine in patients suffering from CHF who are not treated with amiodarone.

In conclusion, our observations suggest that the addition of oral amiodarone to the infusion of dobutamine in patients presenting with CHF refractory to standard treatment attenuates the proarrhythmic effects of dobutamine.

**References**

2. Gibelin P, Sbirrazzuoli V, Drici M, Camous J, Lapalus P, Morand P. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, nor-


31. Kallergis EM, Vardas PE. Primary prevention of sudden cardiac death: apart from the defibrillator, what is important in patients with myocardial infarction or heart failure? Hellenic J Cardiol. 2007; 48; 89-93.